ANXA1 in breast cancer prognosis

Open paper intelligence

ANXA1-positive breast tumors clustered with poor-prognosis features (high grade, basal/TN, BRCA1/2) and worse outcomes in some high-risk subgroups such as HER2+.

Source

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis

Sobral-Leite M, Wesseling J, Smit VT, et al. · BMC medicine · 2015

doi.org/10.1186/s12916-015-0392-6 Read the full paper ↗47 citationscc by

Study at a glance

Design: Cohort — Pooled BCAC tumour series plus familial BRCA cases; ANXA1 IHC associations
N: N=5752 · BCAC patients in primary analyses; plus familial BRCA cases in secondary analyses
Population: Women with breast cancer in pooled BCAC cohorts (mostly non-BRCA carriers)
Outcome: ANXA1 associations with tumour subtype markers and breast-cancer-specific survival

Structured fields used in claim comparison tables when every cited study has a complete layer.

What they did

Pooled BCAC tumor series (5,752 patients plus familial BRCA cases) assessed ANXA1 expression associations with subtype markers and breast-cancer survival.

What they found

High-grade tumors had higher ANXA1 odds (OR adj 1.59); ANXA1 linked to basal-like/TN features; HER2+ ANXA1-overexpressing cases had worse 10-year BCSS (HR adj 1.70).

The limits

What it doesn't show

Does not prove ANXA1 is a ready clinical assay or establish chemotherapy predictive use without further trials.

Key terms

ANXA1: Annexin A1 protein assayed in tumor tissue.
BCAC: Breast Cancer Association Consortium pooled cohorts.
Triple negative: ER/PR/HER2-negative tumors enriched for ANXA1 positivity.
BCSS: Breast cancer-specific survival.
HER2+: HER2-overexpressing subtype where ANXA1 related to worse outcome.
Basal-like markers: EGFR and/or CK5/6 positivity associated with ANXA1.

Flashcards

1 / 10

Research intelligence for this paper

See its role on concept claims, tensions it is part of, placement history, and related discoveries.

Open paper intelligence

Quiz yourself

1 / 6

BCAC N roughly?

Common questions

How many BCAC patients?

5,752 (plus 107 BRCA1/2 familial cases).

Grade association?

OR adj 1.59 for grade 2–3 ANXA1 positivity.

HER2+ survival?

10-year BCSS HR adj 1.70 with ANXA1 overexpression.

Bottom line?

ANXA1 marks aggressive biology; prognostic role needs further study.